Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IR Viloxazine · 1 trial · 1 indication
The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population
| Arm | Type | Description |
|---|---|---|
| IR Viloxazine | EXPERIMENTAL | Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day |
| Placebo | PLACEBO_COMPARATOR | Treatment B: Placebo capsules administered orally 3 times a day |
| Name | Type | Description |
|---|---|---|
| IR Viloxazine | DRUG | One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1. Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6. |
| Placebo | DRUG | Placebo capsules administered orally 3 times a day |
Inclusion criteria: 1. Able to provide informed consent prior to any study procedure being conducted. 2. Capable and willing to comply with study procedures. 3. Male or female aged 18 to 64, inclusive. 4. Subjects with a current diagnosis of ADHD as confirmed by the Conners' Adult ADHD Diagnostic I...
IR Viloxazine is an investigational small molecule being studied for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in adult patients with ADHD.
IR Viloxazine is being developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SUPN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with ADHD.
IR Viloxazine is currently in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The drug is being studied for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult patients.
IR Viloxazine has one completed clinical trial, NCT01107496, titled 'Evaluation of Immediate-Release Viloxazine in Adults With ADHD'. This Phase 1 study was a randomized, double-blind, placebo-controlled trial conducted in the United States with 52 adult participants.
IR Viloxazine is a small molecule being developed for ADHD. Its specific molecular target has not been disclosed in available information. The drug is being evaluated in clinical trials to determine its safety and efficacy in treating ADHD symptoms.